Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...

Spravato is now the first-ever stand-alone therapy for treatment-resistant depression, and is on its way to becoming a ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson's nasal spray, Spravato, to allow it to be used ...

Spravato is a first-of-its-kind medication to help manage treatment-resistant depression, according to Johnson & Johnson. President Donald Trump 'fires' four presidential appointees New England ...

The U.S. Food and Drug Administration on Tuesday approved the first nasal spray that will help with treating major depressive ...

Johnson & Johnson has announced that the U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal ...

CIII nasal spray, marking the first monotherapy to be approved for adults with treatment-resistant depression (TRD).

JNJ stock reporting earnings, expecting $2 EPS and $22.44B revenue, approval for Spravato, mixed chart signals, $167.71 price target - 13% upside ...

FDA approves Johnson & Johnson's Spravato nasal spray as a monotherapy for major depressive disorder, showing superior ...

The drug is now cleared for use as a standalone treatment for depression. Spravato is made from esketamine, one of two mirror ...

Esketamine (Spravato; Johnson & Johnson) is now the first and only monotherapy for adults with major depressive disorder (MDD ...

A non-invasive form of treatment for clinical depression is hoping to provide even faster results thanks to new research.